Abstract: An adaptive voltage source, comprising a signal output end, and a reference resistance forming circuit and a sensing module connected in series between a voltage source and a low power level; the sensing module comprises a sensing end coupled to a transistor to be sensed to sense the threshold voltage drift of the transistor to be sensed in a device circuit; the equivalent resistance of the sensing module increases with the increase of the sensed threshold voltage drift; and the signal output end is coupled to a first node coupled to the reference resistance forming circuit and the sensing module, and is used to output adaptive voltage. The output adaptive voltage is adjusted via the threshold voltage drift sensed by the sensing module. Based on the circuit, also disclosed are a shift register and unit thereof, and display.

Abstract: An ultraviolet light sensing circuit and sensing system. The ultraviolet light sensing circuit comprises a modulation unit and a phase delay unit, wherein the modulation unit comprises a first stage of inverter which is used for sensing ultraviolet light and is used as a voltage feedback modulation stage; and the phase delay unit comprises N stages of inverters which are connected in sequence, where N is an even number which is greater than or equal to 2. The modulation unit is connected to the phase delay unit in sequence, and the output voltage of the phase delay unit is fed to the modulation unit; and the modulation unit is modulated by a control signal which is a pulse signal. The ultraviolet light sensing circuit and sensing system can be used for ultraviolet light information communications. The ultraviolet light sensing circuit can sense ultraviolet light signals and output amplitude modulation wave signals.

Abstract: Disclosed is a method for preparing an insulin glargine (GlyA21-ArgB31-AryB32-human insulin) crystal, comprising crystallizing the insulin glargine at pH 7.0-9.0 and in a crystallization solution containing a recombinant insulin glargine, an organic solvent of a 10-30% concentration by volume, a zinc compound, a phenol derivative, a salt and an organic acid.

Abstract: The present invention relates to substituted indole derivatives, to processes for their production, to new stable forms, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Abstract: Disclosed are a process and catalysts useful for carrying out asymmetric methlyallylations. The catalysts used in the invention have the formula (IV): wherein X1, X2, R3 and R4 are as defined herein. Compounds made by the process of the invention can be used to prepare pharmaceutically active compounds such as 11-?-hydroxysteroid hydrogenase type 1 (11-?-HSD1) inhibitors including 1,3-disubstituted oxazinan-2-ones.

Abstract: Compound of Formula A and pharmaceutically acceptable salts thereof and crystalline Forms I and II of Compound of Formula A! Also, methods for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for their uses.

Abstract: Compound of Formula A and pharmaceutically acceptable salts thereof and crystalline Forms I and II of Compound of Formula A! Also, methods for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for their uses.

Abstract: Disclosed are a process and catalysts useful for carrying out asymmetric methlyallylations. The catalysts used in the invention have the formula (IV): wherein X1, X2, R3 and R4 are as defined herein. Compounds made by the process of the invention can be used to prepare pharmaceutically active compounds such as 11-?-hydroxysteroid hydrogenase type 1 (11-?-HSD1) inhibitors including 1,3-disubstituted oxazinan-2-ones.

Abstract: Disclosed is a method for preparing an insulin glargine (GlyA21-ArgB31-AryB32-human insulin) crystal, comprising crystallizing the insulin glargine at pH 7.0-9.0 and in a crystallization solution containing a recombinant insulin glargine, an organic solvent of a 10-30% concentration by volume, a zinc compound, a phenol derivative, a salt and an organic acid.

Abstract: The present invention is directed to an improved process for the preparation of Compounds of Formula (I) or salts thereof which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid or salt thereof which is useful in the treatment of HIV infection.

Abstract: The present invention is directed to an improved process for the preparation of Compounds of Formula (I), which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid, which is useful in the treatment of HIV infection.

Abstract: An arbitration method and device for arbitrating receiving conflict in a multi-mode multi-SIM multi-standby communication terminal is provided. The method includes: determining if there are at least two cards to receive messages in a time cycle while all of the cards are in standby states, the time cycle being a radio frame of one card; identifying types of messages to be received by the at least two cards after determining there are at least two cards to receive messages in the time cycle, and the types of messages comprising paging message and broadcast message; determining if a receiving conflict occurs; and arbitrating based on the types of receiving conflicts and obtaining arbitration results after determining there is a receiving conflict. The arbitration results include: receiving a paging message preferentially; receiving the paging message with the longest paging period; and receiving the broadcast message with the highest priority.

Abstract: Compound of Formula A and pharmaceutically acceptable salts thereof and crystalline Forms I and II of Compound of Formula A! Also, methods for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for their uses.

Abstract: An arbitration method and device for arbitrating receiving conflict in a multi-mode multi-SIM multi-standby communication terminal is provided. The method includes: determining if there are at least two cards to receive messages in a time cycle while all of the cards are in standby states, the time cycle being a radio frame of one card; identifying types of messages to be received by the at least two cards after determining there are at least two cards to receive messages in the time cycle, and the types of messages comprising paging message and broadcast message; determining if a receiving conflict occurs; and arbitrating based on the types of receiving conflicts and obtaining arbitration results after determining there is a receiving conflict. The arbitration results include: receiving a paging message preferentially; receiving the paging message with the longest paging period; and receiving the broadcast message with the highest priority.

Abstract: Disclosed are syntheses of 11?-HSD1 inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes, metabolic syndrome, obesity, glucose intolerance, insulin resistance, hyperglycemia, hypertension, hypertension-related cardiovascular disorders, hyperlipidemia, deleterious gluco-corticoid effects on neuronal function (e.g. cognitive impairment, dementia, and/or depression), elevated intra-ocular pressure, various forms of bone disease (e.g., osteoporosis), tuberculosis, leprosy (Hansen's disease), psoriasis, and impaired wound healing (e.g., in patients that exhibit impaired glucose tolerance and/or type 2 diabetes).

Abstract: Compound of Formula A and pharmaceutically acceptable salts thereof and crystalline Forms I and II of Compound of Formula A! Also, methods for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for their uses.

Abstract: The present invention discloses an antireflective coating composition for applying between a substrate surface and a positive photoresist composition. The antireflective coating composition is developable in an aqueous alkaline developer. The antireflective coating composition comprises a polymer, which comprises at least one monomer unit containing one or more moieties selected from the group consisting of a lactone, maleimide, and an N-alkyl maleimide; and at least one monomer unit containing one or more absorbing moieties. The polymer does not comprise an acid labile group. The present invention also discloses a method of forming and transferring a relief image by using the inventive antireflective coating composition in photolithography.

Abstract: Disclosed are syntheses of 11?-HSD1 inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes, metabolic syndrome, obesity, glucose intolerance, insulin resistance, hyperglycemia, hypertension, hypertension-related cardiovascular disorders, hyperlipidemia, deleterious gluco-corticoid effects on neuronal function (e.g. cognitive impairment, dementia, and/or depression), elevated intra-ocular pressure, various forms of bone disease (e.g., osteoporosis), tuberculosis, leprosy (Hansen's disease), psoriasis, and impaired wound healing (e.g., in patients that exhibit impaired glucose tolerance and/or type 2 diabetes).

Abstract: Organic coating compositions, particularly antireflective coating compositions, are provided that can be developed with an aqueous alkaline developer, including in a single step during development of an overcoated photoresist layer. Preferred coating compositions comprise a tetrapolymer that comprises at least four distinct functional groups.

Abstract: The present invention discloses a composition suitable for use as a top antireflective coating and barrier layer for 193 nm lithography. The inventive composition is soluble in aqueous base solutions and has low refractive index at 193 nm. The inventive composition comprises an aqueous base-soluble polymer having a backbone and a fluorinated half ester moiety. The fluorinated half ester moiety is pendant from the backbone. The present invention also discloses a method of forming a patterned layer on a substrate by using the inventive composition in lithography.